

Special Issue

Therapeutic Strategies for Metastatic Melanomas

Message from the Guest Editors

Over the last few years, the prognosis of metastatic melanoma patients has improved significantly due to new treatment options, such as checkpoint inhibition and targeted therapy. However, most efficacy data were obtained from randomized phase III trials with strict inclusion and exclusion criteria. As a consequence, there is a great need for data from clinical practice (real world data), for example, from registries that also address patients with, e.g., comorbidities or noncutaneous melanomas that were excluded in the clinical trials.

This Special Issue will highlight the current status of metastatic melanoma therapy and potential future prospects.

Manuscripts are welcome that report on original data or updated, comprehensive literature reviews in the field of melanoma therapy.

Guest Editors

Dr. Andrea Forschner

University Hospital Tuebingen, Eberhard Karls University of Tübingen,
D-72076 Tübingen, Germany

Dr. Elisabeth Livingstone

Department of Dermatology, University Hospital Essen, 45122 Essen,
Germany

Deadline for manuscript submissions

closed (1 May 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/44385

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)